Giant cell tumors of the tendon sheath (GCTTS ... Usually, one joint is involved like the knee or hip. Surgery is the most common treatment to remove the tumors and the inflamed joint tissue.

has granted Fast Track designation to emactuzumab for the treatment of tenosynovial giant cell tumors (TGCT) in patients who are not amenable to or would not benefit from surgery. TGCT is a non ...

Emactuzumab has received fast track designation from the U.S. FDA for patients with tenosynovial giant cell tumors and who would not benefit from surgery. Treatment with emactuzumab has received fast ...

The primary approach to treating TGCT is surgery, often supplemented by ... for adult patients with symptomatic tenosynovial giant cell tumor that leads to significant morbidity or functional ...

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...

The FDA approved the small-molecule inhibitor vimseltinib (Romvimza) for adults with symptomatic tenosynovial giant cell tumor (TGCT ... symptomatic TGCT for whom surgery could worsen functional ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition ...

for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. The FDA previously ...

Dr. William Tap led the development of vimseltinib for tenosynovial giant cell tumor. The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare ...